Keywords: pharma, sales, soften, blow, asian, crisis, ucb
Pharma Sales Soften Blow Of Asian Crisis At UCB
Article | 03 August 1998
UCB, the Belgian pharmaceutical, chemical and film group, has posted netprofits of 3.86 billion Belgian francs ($104.7 million) for the first half ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
